Deal Structure Guide
How Milestone Structures Work in Biotech Licensing
Development, regulatory, and commercial milestones — what pays, what doesn't, and how to model achievability.
What milestone payments are
Milestone payments are contingent consideration paid by a licensee to a licensor upon the achievement of pre-specified events during the life of a licensing agreement. They represent a risk-sharing mechanism: the licensor receives less upfront in exchange for the potential to capture additional value as the program advances.
In biopharma licensing, milestones typically fall into three categories: development milestones (IND filing, first patient dosed, Phase 2 initiation, Phase 3 data readout), regulatory milestones (NDA/BLA filing, FDA approval, EMA approval, approval in additional territories), and commercial milestones (first commercial sale, net sales thresholds — typically $500M, $1B, $2B).
The total contractual milestone package — often called the "biobucks" — is the sum of all possible milestone payments. This number appears in press releases and is almost always misleading. It represents the theoretical maximum, not the expected value. No deal in history has paid out 100% of its contractual milestones.
How milestones are structured and triggered
Milestone structures follow a staircase pattern. Each successive milestone is gated by the achievement of prior milestones, and each carries a larger payment reflecting the de-risking that has occurred.
A typical Phase 2-stage global license might structure milestones as follows: $15M at Phase 3 initiation, $25M at positive Phase 3 data, $30M at NDA/BLA filing, $50M at FDA approval, $30M at EMA approval, $15M at approval in Japan, $25M at first commercial sale, $50M at $500M in net sales, $75M at $1B in net sales, and $100M at $2B in net sales. The total contractual package: $415M.
But the expected value of this milestone package is far lower. Each milestone carries its own probability of achievement, and those probabilities are multiplicative. If the Phase 3 trial has a 55% probability of success, and FDA approval (conditional on positive data) has an 85% probability, the combined probability of reaching FDA approval is approximately 47%. Applied to the milestone amounts, the probability-weighted value might be $120-160M — less than 40% of the headline number.
Two structural elements matter most in negotiation: the definition of the triggering event and the payment timing. Ambiguous trigger definitions — "positive Phase 3 data" without specifying which endpoint, which statistical threshold, or which patient population — create disputes. Payment timing provisions that allow 30-90 days post-achievement give licensees flexibility that can feel like delay to licensors watching their runway.
Achievability rates from the database
Our proprietary database tracks milestone achievability across the full spectrum of biopharma licensing transactions. The data reveals a consistent hierarchy.
Regulatory milestones achieve at the highest rate: approximately 61% of regulatory milestones in our dataset have been paid. This is intuitive — by the time a program reaches regulatory submission, most clinical risk has been retired.
Development milestones achieve at roughly 38%. The dropout is steepest between Phase 2 initiation and Phase 3 data readout, where the clinical failure rate compounds against milestone achievability.
Commercial milestones achieve at approximately 23%. Even approved drugs frequently fail to reach the $1B and $2B sales thresholds embedded in most commercial milestone structures. The gap between approval and commercial success — driven by market access, competitive dynamics, and launch execution — is consistently underestimated in deal models.
Therapeutic area matters. Oncology development milestones achieve at 42%, above the cross-TA average, driven by higher Phase 3 success rates for targeted therapies. CNS development milestones achieve at 28%, the lowest of any major TA, reflecting the persistent difficulty of CNS clinical development.
Explore milestone benchmarks by stage, TA, and deal type on Solidus at calculator.ambrosiaventures.co.
What most companies get wrong
The most common mistake is optimizing for total contractual value. Licensors who negotiate for larger biobucks numbers — pushing commercial milestones from $1B to $2B thresholds, for example — may be trading achievable value for headline value. A $50M milestone at $500M in net sales is worth more than a $100M milestone at $2B in net sales in almost every probability model.
The second mistake is underweighting the importance of diligence obligations. A licensing agreement without meaningful diligence requirements — minimum spend commitments, development timelines, and defined consequences for failure to advance — gives the licensee the option to shelve the program without triggering milestone obligations. This is equivalent to the licensor selling a call option at below-market prices.
The third mistake is failing to model milestone stacking across territories. A deal with separate regulatory milestones for FDA, EMA, and PMDA approval needs a clear payment order and no cross-territory conditionality. Some agreements make EMA milestone payments conditional on prior FDA approval — meaning a program that goes to Europe first may never trigger its US regulatory milestones.
The fourth mistake is ignoring the time value of milestones. A $50M milestone payment 8 years from signing is worth roughly $30M in present value at a 7% discount rate. When comparing offers, licensors need to model on a PV-adjusted basis, not on face value.
Related Insights
Further reading from our research.
Bring us your transaction.
We’ll meet you at peer level — anywhere in the world.